Literature DB >> 18258752

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.

Núria de la Iglesia1, Genevieve Konopka, Sidharth V Puram, Jennifer A Chan, Robert M Bachoo, Mingjian J You, David E Levy, Ronald A Depinho, Azad Bonni.   

Abstract

Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN-Akt-FOXO axis and the leukemia inhibitory factor receptor beta (LIFRbeta)-STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258752      PMCID: PMC2238667          DOI: 10.1101/gad.1606508

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  73 in total

Review 1.  Cell cycle and death control: long live Forkheads.

Authors:  Boudewijn M T Burgering; Geert J P L Kops
Journal:  Trends Biochem Sci       Date:  2002-07       Impact factor: 13.807

2.  Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3.

Authors:  Karni Schlessinger; David E Levy
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.

Authors:  Mrinal K Ghosh; Pankaj Sharma; Phyllis C Harbor; Shaik O Rahaman; S Jaharul Haque
Journal:  Oncogene       Date:  2005-11-10       Impact factor: 9.867

4.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

Authors:  Hui-Wen Lo; Sheng-Chieh Hsu; Mohamed Ali-Seyed; Mehmet Gunduz; Weiya Xia; Yongkun Wei; Geoffrey Bartholomeusz; Jin-Yuan Shih; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

5.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.

Authors:  Xiaoyang Ling; Ralph B Arlinghaus
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

6.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

7.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

8.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 9.  Mutant epidermal growth factor receptors as targets for cancer therapy.

Authors:  I A J Lorimer
Journal:  Curr Cancer Drug Targets       Date:  2002-06       Impact factor: 3.428

10.  c-erbB-3: a nuclear protein in mammary epithelial cells.

Authors:  Martin Offterdinger; Christian Schöfer; Klara Weipoltshammer; Thomas W Grunt
Journal:  J Cell Biol       Date:  2002-06-03       Impact factor: 10.539

View more
  162 in total

1.  STAT3 tyrosine phosphorylation influences survival in glioblastoma.

Authors:  Peter Birner; Kalina Toumangelova-Uzeir; Sevdalin Natchev; Marin Guentchev
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  Identifying disease genes and module biomarkers by differential interactions.

Authors:  Xiaoping Liu; Zhi-Ping Liu; Xing-Ming Zhao; Luonan Chen
Journal:  J Am Med Inform Assoc       Date:  2011-12-20       Impact factor: 4.497

3.  Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.

Authors:  Utpal K Mukhopadhyay; Patrick Mooney; Lilly Jia; Robert Eves; Leda Raptis; Alan S Mak
Journal:  Mol Cell Biol       Date:  2010-08-23       Impact factor: 4.272

4.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

Review 5.  Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.

Authors:  Y-N Wang; H Yamaguchi; J-M Hsu; M-C Hung
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

6.  Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.

Authors:  Daniel R Premkumar; Esther P Jane; Ian F Pollack
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 7.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

Review 8.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

Review 9.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

10.  cAMP-stimulated transcription of DGKθ requires steroidogenic factor 1 and sterol regulatory element binding protein 1.

Authors:  Kai Cai; Marion B Sewer
Journal:  J Lipid Res       Date:  2013-04-22       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.